Cognitive Therapy Versus Medication for Moderate to Severe Depression

2005 ◽  
Author(s):  
2004 ◽  
Author(s):  
Robert J. Derubeis ◽  
Jay D. Amsterdam ◽  
John P. O'Reardon ◽  
Paula R. Young

Author(s):  
Daniel Barron ◽  
Robert Ostroff

This chapter provides a summary of a landmark study on major depressive disorder. Is paroxetine or cognitive therapy more effective in treating patients with moderate to severe major depressive disorder? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case.


2005 ◽  
Vol 62 (4) ◽  
pp. 417 ◽  
Author(s):  
Steven D. Hollon ◽  
Robert J. DeRubeis ◽  
Richard C. Shelton ◽  
Jay D. Amsterdam ◽  
Ronald M. Salomon ◽  
...  

2005 ◽  
Vol 62 (4) ◽  
pp. 409 ◽  
Author(s):  
Robert J. DeRubeis ◽  
Steven D. Hollon ◽  
Jay D. Amsterdam ◽  
Richard C. Shelton ◽  
Paula R. Young ◽  
...  

Mindfulness ◽  
2021 ◽  
Author(s):  
Matilde Elices ◽  
Víctor Pérez-Sola ◽  
Adrián Pérez-Aranda ◽  
Francesc Colom ◽  
Maria Polo ◽  
...  

Abstract Objectives Evidence suggests the efficacy of mindfulness-based cognitive therapy (MBCT) to prevent depression relapse and decrease depressive symptoms during the acute phase. However, the effectiveness of MBCT in real-world heterogeneous samples treated in clinical health settings, including primary care, has received little attention. This study had two aims: (1) to evaluate the effectiveness of MBCT delivered in primary care considering pre-treatment depression scores and (2) to explore the role of participants’ characteristics on symptom improvement. Methods Data were obtained from 433 individuals who received MBCT. Participants completed the Personality Inventory for ICD-11 (PiCD) pretreatment and the Beck Depression Inventory (BDI-II) pre- and post-treatment. Results Sixty percent presented moderate-to-severe depression according to scores on the BDI-II, 18.1% presented mild depression, and 21.7% were in the non-depressed range. The severity of pre-treatment depressive symptoms was associated with outcomes. Most individuals who lacked depressive symptoms at baseline remained in the non-clinical range after the treatment. Those in the severe group benefited the most from the intervention, since 35.6% were considered recovered. Rates of deterioration ranged from 2.1 to 2.7%, depending on the depression-baseline scores. Depression severity at the entrance, attendance, and age, but not personality traits, appear to be related to symptom improvement. Conclusions According to our results, MBCT can be effectively and safely delivered in primary care.


Sign in / Sign up

Export Citation Format

Share Document